Gathering the record
Relay is organizing the evidence and source boundaries.
Urine-derived gonadotropin protein biologic mixture
A fertility medicine containing two types of reproductive hormone activity. It is a mixture, rather than one short peptide.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Controlled fertility studies and FDA product labels support defined uses under specialist monitoring.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Approved labels warn about ovarian hyperstimulation, multiple gestation, thromboembolic events, and other serious reproductive-treatment risks requiring specialist monitoring.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceApproved labels warn about ovarian hyperstimulation, multiple gestation, thromboembolic events, and other serious reproductive-treatment risks requiring specialist monitoring.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Instructions from the named approved product’s prescribing information. They apply to its stated formulation, route, use, and population.
This first-cycle schedule is for women undergoing assisted reproductive technology with specialist monitoring.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| First 5 days, then monitored adjustment; no more than 20 days | 225 IU/day initially | Daily |
The label limits adjustments to 150 IU at a time and total dosing to 450 IU/day. Ultrasound and hormone response guide changes. This does not establish male fertility dosing; IU are not syringe markings.
Menopur · U.S. prescribing information Prescribing information · Dosage and administrationThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.Menopur is supplied with product-specific diluent and instructions. Use the complete instructions for that presentation; do not substitute a generic bacteriostatic-water recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A randomized fertility study compared menotropins with recombinant follicle-stimulating hormone in women undergoing assisted reproduction.
Population: Women undergoing assisted reproduction
Design: Randomized assessor-blind multinational IVF trial
Mechanisms
Menotropins stimulate ovarian follicular development or spermatogenesis through gonadotropin receptors. It is a protein-biologic preparation, not a single short peptide.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Mature human fertility evidence and product-specific regulatory labeling.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
How any non-authorized or differently sourced preparation compares with an approved product in potency, purity, immunogenicity, and clinical outcomes.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The outcomes depend on the specific product, fertility protocol, population, and laboratory program. The study does not support unsupervised use or transfer of potency and handling assumptions to nonauthorized preparations. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized assessor-blind multinational IVF trial
Women undergoing assisted reproduction
Endpoints were not fully described in the current record.
HP-hMG was non-inferior to recombinant FSH for ongoing pregnancy; superiority was not established.
Study administration: Not stated in the current record.
Limitations: Outcomes are protocol-, product-, population-, and laboratory-specific.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 16873892 · DOI 10.1093/humrep/del284